Sustained Release Excipients Market Overview
The Sustained Release Excipients Market is expanding as pharmaceutical companies increasingly adopt advanced drug delivery systems designed to provide prolonged therapeutic effects, improve bioavailability, and enhance patient compliance. Rising chronic disease prevalence, growing demand for patient-centric formulations, advances in material science, increasing pharmaceutical R&D investment, and regulatory support for innovative formulations are supporting market growth.
According to the Market Research Future report updated August 24, 2026, the global Sustained Release Excipients Market was valued at USD 1.50 Billion in 2024 and is projected to grow from USD 1.62 Billion in 2025 to USD 3.498 Billion by 2035, registering a CAGR of 8.0% during 2025–2035. North America remains the largest market, supported by increased R&D activity and the presence of major pharmaceutical companies, while Asia-Pacific is the fastest-growing region. Gelatin dominates the product type segment, Polymers are the fastest-growing product category, Oral administration represents the largest route, Transdermal is the fastest-growing route, Targeted Delivery holds the largest technology share, and Microencapsulation is the fastest-growing technology.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.marketresearchfuture.com/sample_request/22077
Key players driving innovation and competitiveness in the Sustained Release Excipients Market include:
BASF SE
Evonik Industries AG
Ashland Global Holdings Inc.
Dow Inc.
JRS Pharma
Colorcon Inc.
FMC Corporation
Gattefossé
Merck KGaA
Shin-Etsu Chemical Co., Ltd.
The market is being shaped by growing demand for advanced drug delivery systems, increasing focus on patient-centric therapies, rising chronic disease prevalence, and advances in material science. Gelatin remains the dominant excipient type because of its biocompatibility and established pharmaceutical applications, while polymers are gaining momentum because they can provide tailored drug-release profiles. Oral delivery remains the leading route because of convenience and patient adherence, while transdermal technologies are attracting attention as non-invasive sustained-release alternatives.
The Sustained Release Excipients Market can be segmented by Product Type into Gelatin, Polymers, Minerals, Sugars, and Others. By Route of Administration, it includes Oral, Intramuscular, Subcutaneous, Transdermal, Intravenous, and Others. By Technology, it covers Targeted Delivery, Microencapsulation, Wurster Technique, and Others. By Region, the market includes North America, Europe, Asia-Pacific, and the Rest of the World.
The growing need for controlled and patient-friendly drug delivery is creating opportunities for excipient manufacturers, pharmaceutical companies, specialty chemical providers, CDMOs, and drug-delivery technology developers. Biodegradable excipients, novel polymers, lipid and wax-based materials, personalized drug delivery, microencapsulation, and partnerships between excipient manufacturers and pharmaceutical companies can support market differentiation and expansion.
Recent Developments and Market Trends:
Growing demand for patient-centric drug delivery is encouraging the development of formulations that reduce dosing frequency and improve treatment adherence.
Advancements in material science are supporting the development of innovative polymers and biocompatible materials with tailored drug-release profiles.
Microencapsulation is gaining momentum as manufacturers seek improved stability, bioavailability, and controlled release of active pharmaceutical ingredients.
Biodegradable excipients are creating new opportunities for environmentally friendly sustained-release formulations.
Strategic partnerships and manufacturing expansions are supporting the development and commercialization of next-generation sustained-release excipients.
Reasons to Buy the Report:
Provides comprehensive insights into the Sustained Release Excipients Market dynamics, trends, opportunities, and growth potential.
Helps identify opportunities across gelatin, polymers, minerals, sugars, and other excipient materials.
Offers detailed segmentation analysis across product type, route of administration, technology, and geographic markets.
Includes competitive intelligence covering leading excipient manufacturers, specialty chemical companies, pharmaceutical suppliers, and drug-delivery technology providers.
Supports informed decisions using market forecasts, chronic disease trends, patient-compliance requirements, material-science advances, regulatory developments, and regional opportunities.
Future Outlook:
The future of the Sustained Release Excipients Market will be shaped by increasing demand for advanced drug delivery systems, patient-centric formulations, rising chronic disease prevalence, material-science innovation, and regulatory support for novel formulations. Gelatin should remain the dominant product type, while Polymers are positioned as the fastest-growing category because of their versatility and ability to provide tailored release profiles. Oral administration should remain the leading route due to convenience and patient adherence, while Transdermal delivery is expected to remain the fastest-growing route. Targeted Delivery should continue to hold the largest technology share, while Microencapsulation is positioned for significant growth as pharmaceutical manufacturers seek improved stability and controlled release. North America should retain market leadership, while Asia-Pacific should remain the fastest-growing regional market. Market Research Future projects the market to reach USD 3.498 Billion by 2035 at a CAGR of 8.0%.
➤➤Explore Our Latest Related Reports:
